



Review on Potential Mechanisms Involved in Oxidative Stress in the Pathogenesis of Parkinson's Disease and the Role of Biomarkers

Manjunatha PM and Gayathry P*

Department of Pharmacology, Acharya and BM Reddy College of Pharmacy, India

Abstract

Parkinson's disease is a common, multifactorial neurological disorder caused by the degeneration of dopaminergic neurons in SNpc leads to dopamine deficiency. It is the second common neurodegenerative disease. Risk factors such as genetic and environmental provide an impact on the diseased condition. It was primarily characterized by the overexpression of the clumps of proteinaceous inclusions called Lewy bodies composed of alpha-synuclein & having a marked motor and non-motor feature. Oxidative stress exerts a negative effect in Parkinson's disease, is a significant contributory factor in the progression of disease condition through various mechanisms including reactive oxygen species generation that promotes the oxidation of macromolecules such as lipids, proteins & nucleic acid, mitochondrial dysfunction, neuroinflammation including microgliosis, astrogliosis, lymphocytic infiltration, excitotoxicity. To provide better clinical intervention and treatment, it is essential to find reliable, robust, specific & sensitive biomarkers for Parkinson's disease. It can clearly distinguish the disease from other conditions, monitor its progression, or indicate a positive response to therapeutic intervention. This review covers the mechanisms involved in oxidative stress in the genesis of disease and current potential biomarkers, highlighting their role in Parkinson's disease.

Keywords: Parkinson's disease; Pathogenesis; Neuropathology; Proteins; Oxidative stress; Biomarkers

OPEN ACCESS

*Correspondence:

Gayathry P, Department Of
Pharmacology, Acharya and BM Reddy
College of Pharmacy, Soldevanahalli,
Bangalore, Karnataka, India, Tel:
+8157064340;

E-mail: gayathryp96@gmail.com

Received Date: 01 Jul 2021

Accepted Date: 26 Jul 2021

Published Date: 29 Jul 2021

Citation:

Manjunatha PM, Gayathry P. Review
on Potential Mechanisms Involved in
Oxidative Stress in the Pathogenesis
of Parkinson's Disease and the Role of
Biomarkers. *Ann Short Reports*. 2021;
4: 1068.

Copyright © 2021 Gayathry P. This is
an open access article distributed under
the Creative Commons Attribution
License, which permits unrestricted
use, distribution, and reproduction in
any medium, provided the original work
is properly cited.

Abbreviations

SNpc: Substantia Nigra Pars Compacta; CNS: Central Nervous System; ROS: Reactive Oxygen Species; GABA: Gamma-Aminobutyric Acid; MAO-B: Monoamine Oxidase B; NMDA: N-Methyl-D-Aspartate; HSP: Heat Shock Protein; PINK-1: PTEN-Induced Kinase 1; DLB: Dementia with Lewy Bodies; MSA: Multiple System Atrophy; SNCA: Alpha-Synuclein; DUB: Deubiquitinating Enzyme; UCH: Ubiquitin C-Terminal Hydrolases; SOD: Superoxide Dismutase; NO: Nitric Oxide; 6-OHDA: 6-Hydroxydopamine; ETC: Electron Transport Chain; PUFA: Polyunsaturated Fatty Acid; MPTP: 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine; GDNF: Glial Cell Line-Derived Neurotrophic Factor; iNOS: Inducible Nitric Oxide Synthase; COX-2: Cyclooxygenase-2; MHC: Major Histocompatibility Complex; GSH: Glutathione; CSF: Cerebrospinal Fluid; MDA: Malondialdehyde; BDNF: Brain-Derived Neurotrophic Factor

Introduction

Parkinson's disease is a chronic, progressive neurodegenerative disorder characterized by dopaminergic neuron death that develops in Substantia Nigra Pars Compacta (SNpc) and accumulation of abundant intracellular proteinaceous aggregates called Lewy bodies primarily comprised of fibrillar alpha-synuclein and ubiquitinated protein in some remaining nigral neurons [1]. It is the 2nd top-most prevalent primary neurodegenerative disorder of CNS [2] & was categorized by tremor, gait disorder, bradykinesia, stiffness, and postural instability, weak and clumsy limb [3]. Rather than motor symptoms, several non-motor symptoms that accompany Parkinson's disease are sensory, psychiatric symptoms namely anxiety, depression, sleep disorder, and apathy and cognitive abnormalities include learning, memory, perception, problem-solving [4]. Neuroinflammation has also been assumed to result in oxidative stress, overproduction of cytokines, excessive activation of microglia and other inflammatory mediators, as well as ROS, which accelerate disease progression [5]. Apart from dopamine, well-known other neurotransmitters such

as Glutamate, GABA, Acetylcholine also having a role in Parkinson's disease symptoms [6]. The most pervasive neurodegenerative triggers of Parkinsonism are alpha-synucleinopathies (Lewy Body Disease), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), and Corticobasal Degeneration (CBD). Such ailments are described mainly based on the accumulation of the predominant proteins within degenerated neurons and glial cells. Therefore reliable biomarkers are required for early and accurate disease diagnosis to predict disease incidence and progression, as they can be used as objective and characteristic evaluation indicators of normal biological processes and pathogenic processes of the disease. The appropriate biomarkers- alone or in combination, are used to diagnose and record the progression of Parkinson's disease [7]. The featured gold standard for interpretation of Parkinson's disease is the emergence of SNpc degeneration and the "Lewy pathology". Taken into account, it usually comprises abnormal alpha-synuclein aggregates called Lewy body & Lewy neurites (altogether Lewy Pathology) [8]. The Predominant location of Lewy bodies is chiefly in the brain stem and diencephalon (usually SNpc, dorsal vagal nucleus) [9]. Patients associated with dementia shows the involvement of Lewy bodies and also the aggregation of alpha-synuclein intraneuronal native to the peripheral region such as olfactory and gastrointestinal tract central region include medulla, pons, cortex of nervous system which track the motor symptoms and non-motor symptoms; assisted by the participation of midbrain and ultimately to cortical region of the brain [10,11]. Impairment of subnuclei presents in SNpc along with intense wiping out neuromelanin-laden projections often taken into consideration as the most important trademark of Parkinson's disease [12]. The disease is slightly more common in men than in women and the prevalence of this disease is increasing with age and it affects 1% of the total population above 60 years [13]. Worldwide estimations of Parkinson's disease by WHO showed as 35.6 million [14]. This number would be expected to double between 2005 & 2030, more than triple by 2050 [15,16]. In high-income nations, the estimated age-standardized annual incidence rate is 14 per 100,000 people aged 65 years or older [17]. The average prevalence of Parkinson's disease in developed countries is 0.3% in the general population, 1% in people older than 60 years, and 3% in people older than 80 years; the occurrence rate of disease is estimated to range from 8 to 18 per 100000 person-years [18]. The disease frequency ranges vary from country to country and the rate of occurrence is considerably greater in Europe and North America than in West Africa and Asia [19]. Oxidative stress having an impact on the modulation of activity in the disease progression. In this review, the association between Parkinson's disease & oxidative stress will be conferred with possible mechanisms underlying oxidative stress and highlighting the role of biomarkers.

Pathogenesis

A key characteristic primary hallmark feature of Parkinson's disease is the neurodegeneration in SNpc and nigrostriatal (dopaminergic) tract, resulting in a decrease in striatum dopamine, needed for muscle tone and motor coordination. So an inconsistency between the cholinergic (excitatory) and dopaminergic (inhibitory) striatal mechanism occurs, the way that results in motor dysfunction. Triggering of free radicals in the presence of Fe²⁺ ions, found in basal ganglia mainly by the oxidation of aldehyde dehydrogenase and MAO-B. Glutathione and other defensive mechanism annihilated them and it potentially contributes to neuronal death, often causing lipid membrane and DNA damage. By inducing Ca²⁺ overload *via*

the NMDA receptor, excess stimulation of excitatory transmitter glutamate may trigger 'excitatory' neuronal death. Through the administration of neuroleptics, metoclopramide (dopamine blockers), trigger drug-induced temporary or reversible symptoms of Parkinsonism [20].

Neuropathology

The key pathological characteristic of Parkinson's disease is the loss of dopaminergic neurons in the substantia nigra [21]. Usually, the most grievously infected region of substantia nigra pars compacta is the ventrolateral tier, which comprising neurons that project to the dorsal putamen of the Striatum [22]. Neuronal disruption occurs in several other regions of brain-like, locus coeruleus, Meynert nucleus basalis, pedunclopontine nucleus, raphe nucleus, vagus dorsal motor nucleus, amygdala, and hypothalamus [23]. Many other non-dopaminergic neurotransmitter systems, like cholinergic, adenosinergic, glutamatergic, GABAergic, serotonergic, nor-adrenergic, and histaminergic, are also affected [24]. The pathological hallmark of Parkinson's is the Lewy bodies (Lewy pathology), aggregation of alpha-synuclein protein. Mainly in the neuronal phase, large alpha-synuclein aggregates from round laminated eosinophilic cytoplasmic inclusions in the neuronal body & fibrils made of insoluble alpha-syn (Lewy neurite) polymers are deposited. This accumulation impairs the functioning of the mitochondria, lysosome, and endoplasmic reticulum and interacts with microtubular transport. In advanced Parkinson's disease, the depletion of pigmented neurons leads to gross depigmentation of SN [25] directly correlated with the death of dopaminergic-neuromelanin containing neurons present in SNpc & nor-adrenergic neurons in locus coeruleus [26]. In addition to alpha-synuclein, the molecular components of Lewy bodies including proteins like Ubiquitin, Tau, Parkin, Heat Shock Proteins (HSPs), oxidized or nitrated proteins, cytoskeletal proteins (neurofilaments, microtubule-associated proteins, & tubulin), proteasomal & lysosomal elements [12]. The main staging system of disease by Braak et al. has been proposed to introduce the 6 stages of pathology in Parkinson's disease (Table 1) beginning from the peripheral nervous system progressively affecting the CNS rostrocaudal all-round the brain, in a chronological predictable series [27].

Following the revision of the Braak hypothesis, it indicates the association of pathology with alpha-synuclein is initiated at nasal and intestinal mucosal sites, particularly in olfactory bulb & enteric cell plexuses called the "Dual-hit hypothesis". It implies that, *via* the olfactory pathway, an unknown, possibly infectious, pathogen reaches the brain. Notably, PD patients also have olfactory prodromal deficits. Or the pathogen is transmitted to the intestine by swallowing nasal secretions and it enters the vagus nerve and the CNS. The identification of Lewy Bodies in the intestinal systems, vagus nerve, derives pathological support for this hypothesis [31].

Potential Interaction of Encoded Proteins and their Mutation in Parkinson's Disease

Early potential targets that having a major role in the progression of Parkinson's disease. The aim of understanding the therapeutic targets to comprehend the major pathological changes noted is to effectively alleviate or bring down the progression of the disease [32]. The disease is triggered through the coordinated effects of hereditary and environmental interaction [33]. Most cases are probably to be focused due to on the complex interaction between genes and the environment. The interplay of environment and genes is a problem even in cases with known triggers is likely [34]. Majority of cases

Table 1: Braak six staging concept for Parkinson's disease.

Stages	Lewy Body Assessment
Stage 1, 2	The lesions were primarily observed mainly in the dorsal motor nucleus, reticular formation, anterior olfactory nucleus. Patients were considered as Asymptomatic or Pre-symptomatic, although early non-motor features may be present such as autonomic (example: constipation), olfactory, and sleep-related dysfunction [28].
Stage 3	The SNpc becomes active as the disease progresses with Lewy body pathology. Neuronal loss has been observed in melanized neurons.
Stage 4	Simultaneous entering to temporal limbic cortex Clinical motor features [29].
Stage 5,6	Participation of whole neocortex, high order area such as cortical regions (insular cortex, primary cortical areas) [30].

of this pathological condition cannot be explained by genetic mutation itself. However, the particular gene involved in the genetic pathogenesis of this disorder has been put emphasized by a mutation in a specific gene in hereditary Parkinson's disease [35]. Six gene loci found in association with this diseased condition [36]. Alpha-synuclein, PARKIN, PINK-1, DJ-1, LRRK2, ATP13A2, and UCH-L1 gene mutation, which have been shown a deep involvement [37,38].

Alpha-synuclein

The protein alpha-synuclein is abundantly found in neurons and glia within the CNS and is concentrated in the neuronal structure [39]. This is a small, soluble, acidic protein of 140 amino acid residues, and also it is a monomeric protein, primarily in cytosolic location, and a fraction has been found in mitochondria [40]. Belonging to a family of structurally homologous proteins, synuclein is mainly categorized namely as alpha-synuclein, beta-synuclein, gamma-synuclein [41-43]. The protein aggregates are the neuropathological aspect of the diseased condition which is mainly a central component of the Lewy bodies and Lewy neurites [44]. Various cellular functions which may obstruct and these aggregates are present as in case of Dementia with Lewy Bodies (DLB) & Multiple System Atrophy (MSA) [45]. In general, the immunohistochemistry of α -synuclein is typically a global standard in neuropathological assessment [46]. The three distinct key cognizance emerged with the repeated research findings: (1) α -synuclein pathology is prevalent in the neuritic growth process, (2) it is widespread in varying domains of the brain, (3) it is also noticeable in other synucleinopathies, including in cases of Alzheimer's disease (thus termed LB version of AD), NBIA type 1 (Neurodegeneration with Brain Iron Accumulation, PAF (Pure Autonomic Failure) and in essential tremor [12]. The pathological distribution at both cellular and regional levels varies in each diseased state [47]. It possesses a capacity to adhere to negatively charged cell membrane phospholipid, which occurs through the highly conserved region, N-amphipathic domain, and β -sheet structures on protracted periods of incubation [48,49]. During a pathogenetic process, alpha-synuclein acquires neurotoxic properties so the soluble alpha-synuclein monomers at first form oligomers, then gradually merge to arrange as tiny protofibrils & ultimately big, insoluble alpha-synuclein fibrils (i.e., this aggregates that makeup Lewy pathology), due to lack of proper clearance of lysosomal or ubiquitin-proteasome system [50-52]. The other underlying cause of alpha-synuclein accumulation and aggregation is the occurrence of mutations that raise the risk of alpha-synuclein misfolding and oligomerization or deficiency in the molecular pathways that are concerned with alpha-synuclein degradation or misfolding [53,54]. There have been several independent point mutations identified [55]. Alpha-synuclein mutations are detrimental to dopaminergic neurons because of the alteration of a set of intracellular signal programs

[56]. Most important 6 dominant inherited point mutations (A30P, E46K, H50Q, G51D, A53E & A53T) in the alpha-synuclein gene have been identified as rare causes for familial Parkinson's disease [57,58]. In single point mutation, a conversion of G to A at position 209, which eventually changed the code of the amino acid from Alanine to Threonine at residue 53 (A53T) [59]. The first dominantly inherited mutation in Parkinson's disease to be identified was an A53T alteration of the gene encoding α -synuclein & it causes an extreme phenotypic form of PD frequently followed by dementia [60] and muscle rigidity and bradykinesia are the major clinical characteristics [61]. A53T also causes mitochondrial dysfunction- and cell death pathways mediated by endoplasmic reticulum stress [62]. These mutations can form filaments, aggregates of substantia nigra, and other brainstem neurons in dopamine neurons and make dopamine neurons more vulnerable to oxidative stress [63]. Two other point mutations (A30P, E46K) have been identified & they show the segregation with the disease [64]. The chemical process oligomerization is accelerated by A30P α -synuclein mutation, while the A53T mutation accelerates fibrilization and it accelerates alpha-syn aggregation faster than A30P alpha-syn mutation, because of its capacity to induce fibrilization [56]. The second most major cause of Parkinson's disease is autosomal dominant inherited duplication & triplication of the SNCA gene. Duplication of alpha-synuclein locus results in late-onset autosomal dominant types of PD, as shown in sporadic PD, while triplication of alpha-synuclein locus leads to a more extreme phenotype with earlier age at onset [65].

Ubiquitin C-terminal hydrolase L1 (UCH-L1)

It is graded as a Deubiquitinating enzyme (DUB). The two groups of DUB are; (1) UBPC & (2) UCH, which hydrolyses a small proportion of C-terminal ubiquitin adducts. Multiple UCH isoforms are thought to occur in humans; even so, UCHL-3 is present in all tissues, whereas UCHL-1 is specifically limited to testis or ovaries [66]. Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCH-L1) was the extremely most abundant neuronal-specific ubiquitin recycling enzyme. It is known as neuronal-specific protein PGP 9.5, where, remarkably comprising up to 2% of the total brain protein material [67] and approximately 5% residues exist in synaptic vesicles which have mainly been shown to co-localization with alpha-synuclein [68]. It is vital for the maintenance of axonal health & stability and its loss leads to axonal degeneration and neuronal death [69]. UCHL-1 has three known enzymatic roles: (1) hydrolase activity for Lys48-linked ubiquitin chains targeted for proteasomal degradation; (2) recent newly recognized ATPase-independent dimerization-dependent ubiquitin ligase activity for Lys63 ubiquitin molecule residue; (3) A function in ubiquitin monomer homeostasis, where UCHL-1 tends to modulate free ubiquitin monomer breakdown in the cell [70]. The Ubiquitin proteasome system was a significant cellular pathway that

ubiquitinates disrupted proteins and degrade them *via* 26S proteasome [71]. The irregularities in this pathway lead to the failure to remove & destroy misfolded proteins, which results in the accumulation of misfolded proteins in the cell contribute to the development of inclusion bodies, and cause significant loss of dopaminergic cells [72]. Oxidation of UCHL-1 & following decrease in the enzymatic activity impair neuronal function and its survival leads to the pathogenetic condition. Owing to the solubility is decreased, that lead to a subsequent rise in insoluble UCHL-1 [73,74]. Mutation in the gene UCHL-1 & its variation in protein activity have been found. An Isoleucine 93 to Methionine amino acid mutation (I93M) has been reported as a cause of autosomal dominant Parkinson's disease [75,76].

Parkin

Parkin, an enzyme protein of 465 amino acids of approximately 52,000 M molecular mass encoded by the *PARK2* gene, comprises 12 exons spanning 1.5 Mb [77,78]. It is a protein, consist of a ubiquitin homology domain at its N-terminal, by which it interacts with its protein targets [79] & comprising 2 RING fingers at its c-terminus and has been described as an E3 ubiquitin-protein ligase, needed for ubiquitination of proteins, can be activated by autophosphorylation and is necessary for the ubiquitin-proteasome deterioration of target substrates [80]. It is also an element of the ubiquitin system, is a piece of chief machinery for the degradation of adenosine triphosphate-dependent proteins [81]. This protein appears to unfold when overexpressed in cells. A rise in the amount of unfolded proteins in the Endoplasmic Reticulum (ER) causes what is called endoplasmic reticulum stress [82], resulting outcomes of which is programmed cell death [83]. Interestingly, a broad range of mutations within the Parkin gene, such as exon deletions, duplications, and point mutations, eventually cause autosomal recessive early-onset Parkinsonism [84,85]. Mutations like R42P, R46P, K211N, C212Y, C253Y, C289G, and C441R, causing the defect to its mobilization to depolarized mitochondria & hinder mitophagy, contributes to the progression of a diseased state [86].

DJ-1

It is well known as PARK 7, in which the mutation was attributed to the early incidence of recessive Parkinson's disorder causes abolishing antioxidant activity, display increased vulnerability to oxidative stress, reducing protein stability. A homozygous exon 1 to 5 deletions was the first mutation found in this family, that causes the entire protein deletion [87]. The mutation involved in this gene is extremely rare occurring about 1% to 2% early stage of cases. It suggested being co-localized with mitochondria & up-regulation caused under high-stress conditions. The cellular processes related to DJ-1 include attenuating oxidation, RNA binding, cell transformation & androgen receptor signaling [88]. The analysis of the diseased brain shows the oxidative damage of DJ-1 & increase the total protein content. The mutation which was found in a homozygous or heterozygous state ultimately causes the loss of the function of a protein, involving intracellular oxidation-reduction [89]. Mutant DJ-1 (L166P and M26I) enhance the susceptibility of SHSY5Y cells to oxidative stress by suppressing H₂O₂ neuroprotection and induction of thioredoxin-1 by inhibition of factor 2 signal pathway associated with nuclear factor erythroid2 [90]. The deficiency of DJ-1 in neurons results in the decrease in glutamine reflux, serine biosynthesis strengthened cellular antioxidant response cause the dopaminergic neuronal degeneration [91].

Possible Mechanisms Underlying the Oxidative Stress in Parkinson's Disease

Oxidative stress has been a proposed key part of Parkinson's disease. It describes an imbalance between the levels of Reactive Oxygen Species (ROS) such as free radicals and the biological system's ability to detoxify the reactive intermediates through antioxidants creating a dangerous state that contributes to cellular death. H₂O₂, hydroxyl radical, Nitric Oxide (NO), and superoxide radicals are free radicals that are mainly harmful to cells, while SOD, catalase, glutathione, and uric acid are important antioxidants in the human body [92]. SOD catalyzes the transformation of radicals from superoxide to hydrogen peroxide, by catalase and glutathione peroxidase the hydrogen peroxide converts into water and oxygen. Glutathione peroxidase, which transforms nitrate into nitrite. During the rate-limiting stage of purine catabolism, uric acid is transformed by xanthine oxidase. All components of the cell, including DNA, lipids, and proteins, are destroyed by decreased activity of the antioxidant protection mechanism to defend against free-radical generation, eventually leading to cell death [93]. The relationship between oxidative stress & dopaminergic neuronal degenerations has been further confirmed with toxic substances that can trigger oxidative stress namely 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Rotenone, OHDA [94]. Besides several other neurodegenerative disorders are analogous to oxidative stress, which indicates oxidative stress was the major contributing mechanism in neuronal degeneration [95].

ROS in neurotoxicity

It is a kind of free radical, unstable molecule containing oxygen and which freely interacts with other molecules present in the cell. The generation of reactive oxygen species inside the cells can induce disruption to DNA, RNA, and proteins and cause cell death [96]. Through several pathways, ROS can be generated through inter-relationship through redox-active metals & oxygen species, like through Fenton and Haber-Weiss reactions or indirect cycles which involve stimulation of enzymes such as nitric oxide synthase or NADPH oxidase [97]. The major free radicals dominant in ROS such as superoxide Anion Radical (O₂⁻), Hydroxyl Radical (•OH), and Hydrogen Peroxide (H₂O₂) [89]. Superoxide anion primarily generated by the electron transport chain mitochondrial complex I and III, is immensely active & can pass effortlessly through the inner mitochondrial membrane, there it will reduce to hydrogen peroxide. It can also be generated by peroxisomes in addition to mitochondria [98]. As catalase present in the peroxisome, H₂O₂ is reduced into the water for preventing its unnecessary aggregation. Once peroxisomes are injured and the enzymes are getting down-regulated, H₂O₂ is released free into the cytosol, provide a way toward oxidative stress [99]. Around 20 percent of the body's oxygen supply is utilized by the brain, & a large fraction of that oxygen is transformed to ROS [100]. This can be produced from many sources in the brain, together in neurons and glial cells by Electron Transport Chain (ETC), a key donor at the mitochondrial level [101,102]. Significant experimental evidence suggests that ROS, which results from abnormal dopamine metabolism, reduction in glutathione level, and elevated levels of iron & calcium depositions in SNpc, is a key contributor to dopaminergic neuronal loss in the diseased brain [103]. In addition, the brain contains a large amount of PUFA, under oxidative stress, eventually leads to lipid peroxidation & will give rise to the production of toxic substances [104].




Figure 1: Neurotoxic microglial activation.

Mitochondrial dysfunction

Many authentications suggested that mitochondrial dysfunction act as a central factor in the pathogenesis of Parkinson's disease [105]. Since mitochondria play multiple roles as the source and target of ROS. It is a complex organelle with several functions. In addition to their role in energy generation, they are actively involved in calcium homeostasis, stress response, and cell death pathways. So that the dysfunction of mitochondria thus contributes to cellular damage and is associated with neurodegeneration [106]. The fundamental source for ROS is the electron transport chain because a small percentage of the superoxide anion is formed during the depletion of O_2 to H_2O [107,108]. The gradient of protons generated by the process of electron transport transversely the inner mitochondrial membrane that undertakes ATP biosynthesis *via* ATP synthase [109]. Some dehydrogenase of Tricarboxylic Acid (TCA) and complexes I, II, III also can produce superoxide anion [71,110]. The first stage in the mitochondrial electron transport chain is catalyzed by complex I (NADH: ubiquinone oxidoreductase). It draws power from NADH oxidation, transfers, and converts ubiquinol to ubiquinone. Ubiquinol is a membrane-soluble carrier that discharges a couple of Complex III electrons [111,112]. Complex II (succinate-coenzyme Q reductase) creates a connection among the tricarboxylic acid cycle & electron transport chain resulting in odd electrons being released to Complex III *via* ubiquinol [113]. By minimizing cytochrome c through ubisemiquinone oxidation & by the passage of protons *via* mitochondrial matrix into the intermembrane space, Complex III (ubiquinone-cytochrome c oxidase) hand-out greatly to proton gradient [114]. Whenever a decline in the electron transport chain, molecular oxygen will absorb electrons *via* Complex III take place in the formation of a superoxide anion [115]. Complex I respiratory chain deficiencies account for the majority of the generation of unfavorable neural apoptosis and are considered one of the primary causes of ROS, which will inturn the inhibit complex 1. It is well observed in platelets, skeletal muscles, fibroblasts, lymphocytes, etc [116,117]. The major complex 1 inhibitors that have a preferential role include MPTP, rotenone [118]. The mechanism underlying the MPTP is, it crosses the BBB & is taken up by the astrocytes, and is metabolized to 1-methyl-4-phenylpyridinium by MAO-B oxidase further let out to extracellular space. 1-Methyl-4-Phenylpyridinium (MPP+) is the amine substrate for dopamine transporter & it is

selectively taken into dopaminergic neurons, so the Complex I of mitochondrial electron transport chain will get disrupted, results in a decline in ATP production and rise in the generation of ROS [119,120]. Rotenone is the other complex 1 inhibitor, was it active in the oxidative damage to proteins and Lewy body-like inclusions [121]. Other evidence of dysfunction of mitochondria-associated with oxidative stress and damage to dopaminergic cells derives from the observation that mutation in genes encoded in proteins such as alpha-syn, parkin, DJ-1, or PINK is associated with hereditary forms of the disease, provides a physiological basis for the pathology of Parkinson's disease [122]. These observations conveyed that the mutation in the protein encoded by genes affect the mitochondrial function and an increase in oxidative stress provides a deleterious condition in the neurodegeneration [123,124].

Neuroinflammation

Neuroinflammatory mechanisms are also likely the essential contributor to the cascade of neuronal degeneration events [125,126]. These mechanisms largely comprised of Microglial activation, astrogliosis, and lymphocytic infiltration [127].

Microglial activation

The concept of neuroinflammation primarily begins with a concept of microglial activation [128]. Microglia are a specialized population of macrophages & components of the innate immunity system found in CNS. They remove damaged neurons & infections are important for maintaining the health of the CNS, which is activated upon brain injury and immune challenge [100]. A major inception of superoxide and nitric oxide is activated microglia, which in turn leads to oxidative & nitrative stress throughout the microenvironment of the brain. By generating other potentially toxic factors, such as glutamate and pro-inflammatory cytokines like TNF-alpha, IL-1 β , IL-6, and IFN- γ & an accompanying relation with alpha-synuclein results of pro-inflammatory mediators in CSF and basal ganglia induce activation of microglia [129,130]. Not only alpha-synuclein but also LRRK2, DJ-1, parkin are also involved, which provide a way for the microglial activation and lead to neurodegeneration [131]. Microglial activation is described as a double-edged sword, such as by eliminating endogenous or exogenous compounds and they act as neuroprotective cells and having a high level of glutathione and glutathione peroxidase, perform to shield them against harmful

hydrogen peroxide level, on the other hand, the death of dopaminergic neuron release oxidized proteins, lipids, and DNA that are identified by microglia as damaged molecules, triggering their activation. In turn, microglial activation leads to an over-production of cytokines, chemokines, ROS, reactive nitrogen species, causing the neurotoxic vicious cycle [132,133] (Figure 1). Plasma and serum analysis have also been showing the upregulation of proinflammatory cytokines and also serum level of MIF (Macrophage Inhibitory Factor) is increased [134]. The receptors for these cytokines are expressed by dopaminergic neurons, implying that they are responsive to these cytokines. For example; TNF alpha receptor-1 is expressed in dopaminergic neurons and increases the expression of this receptor. While cytokines can actively exert toxic effects by binding to their receptors and activating second messenger pathways, they can also indirectly generate cytotoxic effects [135]. The enzymes such as iNOS (inducible Nitric Oxide Synthase) or COX 2, which can also produce toxic reactive species [136].

Astrogliosis

Besides astrogliosis is the other key aspect of neuroinflammation [137]. Astrocytes are glial cells & the most common abundant type of cell in the human brain that are vital for maintaining neuronal health and provide structural and metabolic assistance, regulation of synaptic transmission, H₂O support, and blood flow inside the brain. They provide neurotrophic molecules namely GDNF which is particularly essential for the betterment and survival of dopaminergic neurons [138]. Additionally, when microglia initiates an immune response, astrocytes surround that region gradually builds a shield to obstruct the spreading of the toxic signal to surrounding healthy tissue [139]. Emerging evidence implicating that brain damages such as brain injury, oxidative stress, the function of astrocytes become transiently or permanently disrupted in Parkinson's disease [140,141]. Astrocytes release inflammatory cytokines that may affect surrounding neurons during the process of reactive astrogliosis, also involve both molecular & morphological changes such as induced generation of ROS and lipid peroxidation due to the production of NO by iNOS which may diffuse towards neurons, excessive formation of gap junction between astrocytes, formation of scars, activation of apoptotic mechanisms that cause neuronal dopaminergic death [142,143]. Furthermore, in SN of post-mortem PD patients, the

upregulation of S100b (Calcium-binding proteins) which act as a cytokine, primarily expressed by astrocytes has been shown. This increase in the iNOS production may lead to the activation of COX-2 (proinflammatory enzyme) in microglia, as well as increased NO and superoxide radical formation (Figure 2). The function of astrocytes in disease pathology was not well known also there has been a theory stating that such glial cell which may prevent and or worsen nigrostriatal injury due to disturbed balance [144].

Lymphocytic infiltration

Lymphocyte infiltration is the other major key aspect in neuroinflammation mainly *via* the presence of T lymphocytes, a major endogenous mediator of neuroinflammation. B cells and natural killer cells have not been recognized. Helper T-cells (CD4+, Th) and killer T-cells (CD8+) stand active & will involve in the immune response. Th1, Th17, Granulocyte macrophage-colony stimulating factor-producer T-cells have also been documented to cause the acquisition of neurotoxic microglia to be resulting in increased release of neuroinflammatory cytokines and chemokines [145] (Figure 3). In PD patients, reduced serum levels of naïve lymphocytes were noticed while the number of activated T cells was increased, reflecting that there is a peripheral activation in PD pathology. These data indicate that immunogenic factors produced by impaired dopaminergic neurons have the potential ability to amplify the pathological process by inducing a detrimental immune response [146]. Although activation of microglia and inflammatory changes are commonly seen as a cause of neuronal destruction. In Genome-Wide Association Studies (GWAS), the identification of Human Leukocyte Antigen (HLA) as a causative reason of Parkinson's disease, raises the possibility of increase the widespread in a pro-inflammatory situation in disease, the predominant principle source of neuronal failure in certain conditions, or as a minimum an increasing threat of Parkinson's disease as a genotype modifier [147]. The most apparent immune-related disease risk variants, positioned in the HLA region (HLA-DRB1 & HLA-DRB5) [148]. The Major Histocompatibility Complex (MHC) protein encoded by the HLA gene, which is actively engaged in the presentation of antigen & its immunity. The above complex remains on the surface of antigen-presenting cells such as microglia & facilitate the activation of T cell [149]. Such preliminary findings lift the assumptions that depletion





Figure 2: Role of astrocytes in Parkinson's disease pathogenesis.



of dopaminergic neurons caused by genetic defect or exposure to environmental toxic substances will lead the way for mild to moderate peripheral inflammation [150].

Biomarkers of Oxidative Stress in Parkinson's Disease

Biomarkers are naturally occurring molecule, gene or characteristic that is objectively measured & evaluated as an indicator of normal biologic processes, pathogenic processes or pharmacologic response to a therapeutic intervention [151]. It is an indicator of a particular state of a disease or an organism, normal and abnormal biologic process and could be a chemical, physical, or biological parameter. It is a parameter that can be used to assess disease progression or treatment effects, also supported early diagnosis, disease prevention, drug target identification, and drug response [152]. The characteristics of an ideal biomarker should be sensitive, reproducible, closely correlated with disease pathophysiology, easy to measure; inexpensive, non-invasive, and thoroughly validated [153,154]. The findings reflect that it provides a way to enhance our understandings of PD pathogenesis [155].

8-Hydroxydeoxyguanosine (8-ohdG)

It is one of the DNA lesions caused by the ROS by oxidation of guanine residues and hydroxyl radicals and DNA generates 8-OHdG. The level of this biomarker is selectively increased in diseased patients. It is consistently seen high level in CSF compared to that of standard control [156]. The concentration of this marker is increased in SN, peripheral blood, Urine of Parkinson's disease [157].

Glutathione

Glutathione, which is a most thiol-reducing agent acts as an antioxidant that excludes free radicals that might destruct dopaminergic neurons & could be lethal to dopaminergic neurons thereby acting also as a neuroprotective agent. Overall glutathione contains reduced GSH & oxidized forms, preserves redox homeostasis, eliminates metabolic waste, & provides a reservoir for amino acids

in the brain. Post-mortem assessment of PD patients' nigral tissue showed GSH deficiency, indicating the decreased ability of cellular waste metabolism capacity and protection against ROS, RNS and H₂O₂ [158]. Auto-oxidation of the DA produces H₂O₂ and causes the destruction of GSH. Subsequently, H₂O₂ is transformed into hydroxyl radicals, that are extremely reactive capable of interacting with cellular macromolecules. The formation of hydroxyl radicals catalyzed by iron plays a significant role in the formation of oxidative stress & loss of dopaminergic neuronal loss. The declined level of GSH seen substantia nigra and corpus striatum, suggest that accumulation of hydroxyl radical is elevated due to GSH down-regulation [159].

Coenzyme Q10

Coenzyme Q10 is a constituent of the electron transport chain [160], mainly present in cytosol and plasma. It is a vital cofactor in the mitochondrial respiratory chain, oxidative phosphorylation & regarded as a relevant antioxidant. *In vitro* and *In-vivo* experiments also reported flaws in mitochondrial complex 1 leading to redox equilibrium destruction, leading ultimately to neuronal toxicity. Since it is a lipophilic antioxidant, it will scavenge the radicals present inside the membrane. A reduced concentration of this coenzyme indicated a surge in free radicals, leads to neuronal degeneration. The progression of the disease is substantially retarded by coenzyme Q10 and was clinically accessible as a peripheral biomarker [161].

Lipid peroxidation products

Oxidative degradation of lipids is termed lipid peroxidation. It is promoted by free radicals on membrane lipids, which can abstract hydrogen from the methylene group [162]. Lipid peroxidation interferes with membrane organization, protein, and DNA impairment [163]. Several studies have revealed the altered level of lipid peroxidation products such as isoprostanes, MDA in neurodegenerative brain tissues. The level of HNE (4-Hydroxy-2,3-Nonenal) in CSF is high and the level of MDA [164], isoprostanes is high in the plasma of diseased patients [165]. These studies demonstrated that oxidative stress plays a major role in PD through

lipid peroxidation [166].

Neuromelanin

Catecholaminergic neurons contain neuromelanin, which is a dark polymer pigment & tends to always be wide spread in the human brain, but it is missing from those brains of several smaller animals. Substantia nigra containing neuromelanin are infected in a diseased state [167]. The aggregation of neuromelanin-containing neurons tends to be the defensive phenomenon that avoids different mechanisms of neurotoxicity. It acts as an iron storage system in the substantia nigra dopaminergic neurons where no ferritin has been observed. While in a disease state, the damaged neurons release neuromelanin which will lead to the triggering of the vicious cycle in neuroinflammation [168]. It also guards neurons against oxidative stress facilitated by the free radicals, metals, etc. The rate of neuromelanin can be calculated by magnetic resonance imaging techniques and information on substantia nigra degeneration has been shown to provide and is an important biomarker for Parkinson's disease [169].

Plasma uric acid level

Uric acid is an essential natural antioxidant that behaves like a free radical scavenger & iron chelator that will reduce oxidative stress [170]. It has been found to prevent dopaminergic cell death [171]. The reduced level of uric acid was found in the SN of the diseased population compared to that of the normal population [172]. Moreover, this having a strong binding capacity to iron, leads to oxidative damage by the generation of reactive oxygen species [173]. Urate may be a significant determinant in disease susceptibility & it was found to be decreased in the serum, CSF [174]. The concentration of urate in CSF is approximately 7% than that of plasma. It is found in plasma as a sodium salt. At physiological concentration, it effective as ascorbate to avoid the lipid peroxidation by hydrogen peroxide scavenges nitrogen radicals. Furthermore, the administration of the urate causes the decline in oxidative stress & mitochondrial dysfunction of human dopaminergic neurons due to iron ions, rotenone, etc. In conclusion, it is a risk factor and a prognostic indicator of Parkinson's disease [175].

Serum BDNF

Brain-Derived Neurotrophic factor belongs to a family of neurotrophins that control the survival and functioning of CNF neurons [176]. It is a potent inhibitor of cell death triggered by apoptosis & dopaminergic neurodegeneration by neurotoxins, indicating that it would likely be used in the development of disease therapies [177]. Concerning neurological disorder, the expression of BDNF is decreased, and was found in the nigrostriatal dopamine region [178]. On the other side, the glial cell in the SN of the patients expressed an elevated level of BDNF in response to the signal generated from failing neurons. In the case of 6-OHDA induction, the intra-striatal grafts of fibroblast genetically engineered to develop BDNF partially obstruct the loss of bodies of the nigrostriatal dopaminergic pathway [179]. BDNF not only having a trophic action but also has a potential capacity for the regulation of cognitive processes [180]. The level of BDNF is increased by the use of anti-Parkinson's drugs & it represents a possible peripheral marker in cognitive functioning [181].

Serum IGF-1

An Insulin-like growth factor is put forward as a marker for the early detection and protection from the depletion of dopaminergic

neurons [182]. Moreover, the meta-analysis showed that the signaling pathway of IGF-1 is dysregulated in substantia nigra tissues [183]. Moreover, serum IGF-1 levels were reported to be a threat for Parkinson's disease in people related to altered motor function and transcranial sonography of substantia nigra & closely associated with Unified Parkinson's Disease Rating Scale (UPDRS-III). It was proof of confirmation that it forecast the progression of motor symptoms and executive performances diminish in disease patients [184].

p-Tau and p-Tau/A β 42 ratio

Amyloid-beta 1-42 (A β 42) has been reported to be lower in the Cerebrospinal Fluid (CSF), a biomarker in PD, can be used for predicting cognitive decline in idiopathic Parkinson's disease, though to a lesser extent than that of Alzheimer's disease [185]. This decrease may be due to the monomers being deposited in the brain that restricts their diffusion to the CSF [186]. Also CSF total Tau (t-Tau) & phosphorylated Tau-181 (p-tau), is more complex target than that of A β , lower in PD patients compared to the control population. On the other hand, an elevated level of tau is reported in patients having dementia [187].

Conclusion

Neurodegenerative diseases impose a significant health risk not only on the affected individual but also on their families and society. It becoming more common and rapidly increasing in the aged population worldwide. Although several mechanisms have been hypothesized for the pathogenesis of Parkinson's disease, it remains elusive. The lines of evidence reveal that the oxidative stress underlying Parkinson's disease was complex & it involves multiple mechanisms. Important key contributing factors culpable for oxidative stress are ROS neurotoxicity, dysfunction of mitochondria, dysregulation of immunity, and increase in iron and calcium depositions. What this put forward that, oxidative stress can be an initiator & being a component for neurodegeneration. Nevertheless, an intense investigation has shown that the disease remains incurable. All of these factors lead to excessive production of ROS. When ROS overwhelms the antioxidant defense system, lipid peroxidation, protein oxidation, and DNA oxidation take place. The goal in the development and validation of disease-specific biomarkers is to facilitate the early diagnosis of disease, prediction of progression, and monitoring of therapeutic efficacy. The application of objective biomarkers and the evaluation of oxidative stress is an avenue for the diagnosis of Parkinson's disease.

Author's Contributions

Manjunatha P Mudagal: Drafting the article, Critical revision of the article, Gayathry P: Conception or design of the work, Data collection, Data analysis and interpretation.

References

1. Radhakrishnan DM, Goyal V. Parkinson's disease: A review. *Neurology India*. 2018; 66(7):S26-35.
2. Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, et al. CSF and blood biomarkers for Parkinson's disease. *Lancet Neurol*. 2019;18(6):573-86.
3. Nutt JG, Wooten GF. Clinical practice. Diagnosis and initial management of Parkinson's disease. *N Engl J Med*. 2005;353(10):1021-7.
4. Campbell AW. Parkinson's disease: A brief review. *Adv Mind Body Med*. 2014;28(2):4-5.
5. Tansey MG, Goldberg MS. Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention.

- Neurobiol Dis. 2010;37(3):510-8.
6. Wardas J. Synergistic effect of SCH 58261, an adenosine A2A receptor antagonist, and L-DOPA on the reserpine-induced muscle rigidity in rats. *Pol J Pharmacol*. 2003;55(2):155-64.
 7. Dickson DW. Neuropathology of Parkinson disease. *Parkinsonism Relat Disord*. 2018;46(Suppl 1):S30-3.
 8. Kalia LV, Lang AE. Parkinson disease in 2015: Evolving basic, pathological and clinical concepts in PD. *Nat Rev Neurol*. 2016;12(2):65.
 9. Barbosa, Limongi JCP, Cummings JF. Parkinson's disease. *Psychiatr Clin N Am*. 1997;20(4):769-90.
 10. Brundin P, Ma J, Kordower JH. How strong is the evidence that Parkinson's disease is a prion disorder? *Curr Opin Neurol*. 2016;29(4):459-66.
 11. Homayoun H. Parkinson disease. *Ann Intern Med*. 2018;169(5):ITC33-48.
 12. Braak H, Del Tredici K, Rüb U, De Vos RA, Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol Aging*. 2003;24(2):197-211.
 13. Tysnes OB, Storstein A. Epidemiology of Parkinson's disease. *J Neural Transm (Vienna)*. 2017;124(8):901-5.
 14. WHO. Dementia: A public health priority. World Health Organization; 2012.
 15. Chou KL. In the clinic. Parkinson disease. *Ann Intern Med*. 2012;157(9):ITC5-16.
 16. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkman J, et al. Parkinson disease. *Nat Rev Dis Primers*. 2017;3(1):1-21.
 17. Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: Risk factors and prevention. *Lancet Neurol*. 2016;15(12):1257-72.
 18. Balestrino R, Schapira AH. Parkinson disease. *Eur J Neurol*. 2020;27(1):27-42.
 19. Verma AK, Raj J, Sharma V, Singh TB, Srivastava S, Srivastava R. Epidemiology and associated risk factors of Parkinson's disease among the north Indian population. *Clin Epidemiol Glob Health*. 2017;5(1):8-13.
 20. Sharma UR, Anjali S, Surendra V, Taj N, Manjunatha PM. Parkinson's disease: A brief outlook. *Int J Mol Biotechnol*. 2019;5(2):11-23.
 21. Kalia LV, Lang AE. Parkinson's disease. *Lancet*. 2015;6736(14):61393-3.
 22. Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. *Brain*. 2013;136(8):2419-31.
 23. Dickson DW. Parkinson's disease and Parkinsonism: Neuropathology. *Cold Spring Harb Perspect Med*. 2012;2(8):a009258.
 24. Kalia LV, Brotchie JM, Fox SH. Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials. *Mov Disord*. 2013;28(2):131-44.
 25. Kouli A, Torsney KM, Kuan WL. Parkinson's disease: Etiology, neuropathology, and pathogenesis. In: Stoker TB, Greenland JC, editors. *Parkinson's disease: Pathogenesis and clinical aspects*. Chapter 1. Brisbane (AU): Exon Publications; 2018:3-26.
 26. Xia Q, Liao L, Cheng D, Duong DM, Gearing M, Lah JJ, et al. Proteomic identification of novel proteins associated with Lewy bodies. *Front Biosci*. 2008;13:3850-6.
 27. Khoo TK, Yarnall AJ, Duncan GW, Coleman S, O'Brien JT, Brooks DJ, et al. The spectrum of nonmotor symptoms in early Parkinson disease. *Neurology*. 2013;80(3):276-81.
 28. Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Van Deerlin V, et al. Neuropathologic substrates of Parkinson disease dementia. *Ann Neurol*. 2012;72(4):587-98.
 29. Pavese N, Rivero-Bosch M, Lewis SJ, Whone AL, Brooks DJ. Progression of monoaminergic dysfunction in Parkinson's disease: A longitudinal 18F-dopa PET study. *Neuroimage*. 2011;56(3):1463-8.
 30. Fritsch T, Smyth KA, Wallendal MS, Hyde T, Leo G, Geldmacher DS. Parkinson disease: Research update and clinical management. *South Med J*. 2012;105(12):650-6.
 31. George JL, Mok S, Moses D, Wilkins S, Bush AI, Cherny RA, et al. Targeting the progression of Parkinson's disease. *Curr Neuropharmacol*. 2009;7(1):9-36.
 32. Tanner CM. Advances in environmental epidemiology. *Mov Disord*. 2010;25(S1):S58-62.
 33. Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati M, et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. *N Engl J Med*. 2006;354(4):424-5.
 34. Polymeropoulos MH, Higgins JJ, Golbe LI, Johnson WG, Ide SE, Di Iorio G, et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. *Science*. 1996;274(5290):1197-9.
 35. Snyder H, Wolozin B. Pathological proteins in Parkinson's disease: Focus on the proteasome. *J Mol Neurosci*. 2004;24(3):425-42.
 36. Zeng XS, Geng WS, Jia JJ, Chen L, Zhang PP. Cellular and molecular basis of neurodegeneration in Parkinson disease. *Front Aging Neurosci*. 2018;10:109.
 37. Davie CA. A review of Parkinson's disease. *Br Med Bull*. 2008;86:109-27.
 38. Jakes R, Spillantini MG, Goedert M. Identification of two distinct synucleins from human brain. *FEBS Lett*. 1994;345(1):27-32.
 39. Cole NB, DiEuliis D, Leo P, Mitchell DC, Nussbaum RL. Mitochondrial translocation of α -synuclein is promoted by intracellular acidification. *Exp Cell Res*. 2008;314(10):2076-89.
 40. Clayton DF, George JM. The synucleins: A family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. *Trends Neurosci*. 1998;21(6):249-54.
 41. Galvin JE, Schuck TM, Lee VM, Trojanowski JQ. Differential expression and distribution of α -, β -, and γ -synuclein in the developing human substantia nigra. *Exp Neurol*. 2001;168(2):347-55.
 42. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, et al. Oxidative damage linked to neurodegeneration by selective α -synuclein nitration in synucleinopathy lesions. *Science*. 2000;290(5493):985-9.
 43. Visanji NP, Brooks PL, Hazrati LN, Lang AE. The prion hypothesis in Parkinson's disease: Braak to the future. *Acta Neuropathol Commun*. 2013;1(1):1-2.
 44. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the α -synuclein gene identified in families with Parkinson's disease. *Science*. 1997;276(5321):2045-7.
 45. Kahle PJ. α -Synucleinopathy models and human neuropathology: Similarities and differences. *Acta Neuropathol*. 2008;115(1):87-95.
 46. Goedert M. Alpha-synuclein and neurodegenerative diseases. *Nat Rev Neurosci*. 2001;2(7):492-501.
 47. Davidson WS, Jonas A, Clayton DF, George JM. Stabilization of α -synuclein secondary structure upon binding to synthetic membranes. *J Biol Chem*. 1998;273(16):9443-9.
 48. Narayanan V, Scarlata S. Membrane binding and self-association of α -synucleins. *Biochemistry*. 2001;40(33):9927-34.
 49. Kim C, Lee SJ. Controlling the mass action of α -synuclein in Parkinson's disease. *J Neurochem*. 2008;107(2):303-16.
 50. Melki R. Role of different alpha-synuclein strains in synucleinopathies, similarities with other neurodegenerative diseases. *J Parkinsons Dis*. 2015;5(2):217-27.

51. Wu KP, Weinstock DS, Narayanan C, Levy RM, Baum J. Structural reorganization of α -synuclein at low pH observed by NMR and REMD simulations. *J Mol Biol.* 2009;391(4):784-96.
52. Kaushik S, Cuervo AM. Proteostasis and aging. *Nat Med.* 2015;21(12):1406-15.
53. Xilouri M, Brekk OR, Stefanis L. Alpha-synuclein and protein degradation systems: A reciprocal relationship. *Mol Neurobiol.* 2013;47(2):537-51.
54. Zarranz JJ, Alegre J, Gómez-Esteban JC, Lezcano E, Ros R, Ampuero I, et al. The new mutation, E46K, of α -synuclein causes Parkinson and Lewy body dementia. *Ann Neurol.* 2004;55(2):164-73.
55. Pupyshv AB, Korolenko TA, Akopyan AA, Amstislavskaya TG, Tikhonova MA. Suppression of autophagy in the brain of transgenic mice with overexpression of A53T-mutant α -synuclein as an early event at synucleinopathy progression. *Neurosci Lett.* 2018;672:140-144.
56. Wong YC, Krainc D. α -synuclein toxicity in neurodegeneration: Mechanism and therapeutic strategies. *Nat Med.* 2017;23(2):1-13.
57. Pihlström L, Blauwendraat C, Cappelletti C, Berge-Seidl V, Langmyhr M, Henriksen SP, et al. A comprehensive analysis of SNCA-related genetic risk in sporadic parkinson disease. *Ann Neurol.* 2018;84(1):117-29.
58. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, et al. α -synuclein locus duplication as a cause of familial Parkinson's disease. *Lancet.* 2004;364(9440):1167-9.
59. Periquet M, Fulga T, Myllykangas L, Schlossmacher MG, Feany MB. Aggregated α -synuclein mediates dopaminergic neurotoxicity *in vivo*. *J Neurosci.* 2007;27(12):3338-46.
60. Athanassiadou A, Voutsinas G, Psiouri L, Leroy E, Polymeropoulos MH, Ilias A, et al. Genetic analysis of families with Parkinson disease that carry the Ala53Thr mutation in the gene encoding alpha-synuclein. *Am J Hum Genet.* 1999;65(2):555-8.
61. Smith WW, Pei Z, Jiang H, Moore DJ, Liang Y, West AB, et al. Leucine-Rich Repeat Kinase 2 (LRRK2) interacts with Parkin, and mutant LRRK2 induces neuronal degeneration. *Proc Natl Acad Sci U S A.* 2005;102(51):18676-81.
62. Stefanis L. α -Synuclein in Parkinson's disease. *Cold Spring Harb Perspect Med.* 2012;2(2):a009399.
63. Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Agid Y, et al. Causal relation between α -synuclein locus duplication as a cause of familial Parkinson's disease. *Lancet.* 2004;364(9440):1169-71.
64. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT. Acceleration of oligomerization, not fibrillization, is a shared property of both α -synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy. *Proc Natl Acad Sci U S A.* 2000;97(2):571-6.
65. Liu Y, Lashuel HA, Choi S, Xing X, Case A, Ni J, et al. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. *Chem Biol.* 2003;10(9):837-46.
66. Bishop P, Rocca D, Henley JM. Ubiquitin C-terminal hydrolase L1 (UCH-L1): Structure, distribution and roles in brain function and dysfunction. *Biochem J.* 2016;473(16):2453-62.
67. Nishikawa K, Li H, Kawamura R, Osaka H, Wang YL, Hara Y, et al. Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. *Biochem Biophys Res Commun.* 2003;304(1):176-83.
68. Choi J, Levey AI, Weintraub ST, Rees HD, Gearing M, Chin LS, et al. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. *J Biol Chem.* 2004;279(13):13256-64.
69. Osaka H, Wang YL, Takada K, Takizawa S, Setsuie R, Li H, et al. Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. *Hum Mol Genet.* 2003;12(16):1945-58.
70. Healy DG, Abou-Sleiman PM, Wood NW. Genetic causes of Parkinson's disease: UCHL-1. *Cell Tissue Res.* 2004;318(1):189-94.
71. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. *Nature.* 2006;443(7113):787-95.
72. Setsuie R, Wada K. The functions of UCH-L1 and its relation to neurodegenerative diseases. *Neurochem Int.* 2007;51(2-4):105-11.
73. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the Parkin gene cause autosomal recessive juvenile parkinsonism. *Nature.* 1998;392(6676):605-8.
74. Krüger R, Eberhardt O, Riess O, Schulz JB. Parkinson's disease: One biochemical pathway to fit all genes? *Trends Mol Med.* 2002;8(5):236-40.
75. Halliwell B. Oxidative stress and neurodegeneration: Where are we now? *J Neurochem.* 2006;97(6):1634-58.
76. Zhuang N, Li L, Chen S, Wang T. PINK1-dependent phosphorylation of PINK1 and Parkin is essential for mitochondrial quality control. *Cell Death Dis.* 2016;7(12):e2501.
77. Imai Y, Soda M, Takahashi R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. *J Biol Chem.* 2000;275(46):35661-4.
78. Kumar A, Tamjar J, Waddell AD, Woodroof HI, Raimi OG, Shaw AM, et al. Structure of PINK1 and mechanisms of Parkinson's disease-associated mutations. *Elife.* 2017;6:e29985.
79. Mizuno Y, Hattori N, Mori H, Suzuki T, Tanaka K. Parkin and Parkinson's disease. *Curr Opin Neurol.* 2001;14(4):477-82.
80. Kaufman RJ. Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. *Genes Dev.* 1999;13(10):1211-33.
81. Patil C, Walter P. Intracellular signaling from the endoplasmic reticulum to the nucleus: The unfolded protein response in yeast and mammals. *Curr Opin Cell Biol.* 2001;13(3):349-55.
82. Periquet M, Lücking CB, Vaughan JR, Bonifati V, Dürr A, De Michele G, et al. Origin of the mutations in the Parkin gene in Europe: Exon rearrangements are independent recurrent events, whereas point mutations may result from Founder effects. *Am J Hum Genet.* 2001;68(3):617-26.
83. Sanyal J, Jana A, Ghosh E, Banerjee TK, Chakraborty DP, Rao VR. Evaluation of PARKIN gene variants in West Bengal Parkinson's disease patients. *J Hum Genet.* 2015;60(9):485-92.
84. Narendra DP, Jin SM, Tanaka A, Suen DF, Gautier CA, Shen J, et al. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. *PLoS Biol.* 2010;8(1):e1000298.
85. van Duijn CV, MCJ Dekker V, Bonifati RJ, Galjaard JJ, Houwing-Duistermaat S, Snijders PJ, Breedveld GJ, et al. PARK7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. *Am J Hum Genet.* 2001;69(3):629-34.
86. Abou-Sleiman PM, Healy DG, Quinn N, Lees AJ, Wood NW. The role of pathogenic DJ-1 mutations in Parkinson's disease. *Ann Neurol.* 2003;54(3):283-6.
87. Zhu PP, Stadler J, Klinefelter GR, Blackstone C, Miller DW, Ahmad R, et al. L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome system. *J Biol Chem.* 2003;278(38):36588-95.
88. Im JY, Lee KW, Woo JM, Junn E, Mouradian MM. DJ-1 induces thioredoxin 1 expression through the Nrf2 pathway. *Hum Mol Genet.* 2012;21(13):3013-24.

89. Meiser J, Delcambre S, Wegner A, Jäger C, Ghelfi J, d'Herouel AF, et al. Loss of DJ-1 impairs antioxidant response by altered glutamine and serine metabolism. *Neurobiol Dis.* 2016;89:112-25.
90. Dias V, Junn E, Mouradian MM. The role of oxidative stress in Parkinson's disease. *J Parkinsons Dis.* 2013;3(4):461-91.
91. Wei Z, Li X, Li X, Liu Q, Cheng Y. Oxidative stress in Parkinson's disease: A systematic review and meta-analysis. *Front Mol Neurosci.* 2018;11:236.
92. Muller FL, Liu Y, Van Remmen H. Complex III releases superoxide to both sides of the inner mitochondrial membrane. *J Biol Chem.* 2004;279(47):49064-73.
93. Richardson JR, Quan YU, Sherer TB, Greenamyre JT, Miller GW. Paraquat neurotoxicity is distinct from that of MPTP and rotenone. *Toxicol Sci.* 2005;88(1):193-201.
94. Andersen JK. Oxidative stress in neurodegeneration: Cause or consequence? *Nat Med.* 2004;10:S18-25.
95. Kolodkin AN, Sharma RP, Colangelo AM, Ignatenko A, Martorana F, Jennen D, et al. ROS networks: Designs, aging, Parkinson's disease and precision therapies. *NPJ Syst Biol Appl.* 2020;6(1):34.
96. Smith DG, Cappai R, Barnham KJ. The redox chemistry of the Alzheimer's disease amyloid β peptide. *Biochim Biophys Acta.* 2007;1768(8):1976-90.
97. Beal MF. Bioenergetic approaches for neuroprotection in Parkinson's disease. *Ann Neurol.* 2003;53(Suppl 3):S39-47.
98. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. *Int J Biochem Cell Biol.* 2007;39(1):44-84.
99. Johnson WM, Wilson-Delfosse AL, Mieyal J. Dysregulation of glutathione homeostasis in neurodegenerative diseases. *Nutrients.* 2012;4(10):1399-440.
100. Dumont M, Beal MF. Neuroprotective strategies involving ROS in Alzheimer disease. *Free Radic Biol Med.* 2011;51(5):1014-26.
101. Yan MH, Wang X, Zhu X. Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. *Free Radic Biol Med.* 2013;62:90-101.
102. Jenner P, Olanow CW. The pathogenesis of cell death in Parkinson's disease. *Neurology.* 2006;66(10 suppl 4):S24-36.
103. Liu X, Yamada N, Maruyama W, Osawa T. Formation of dopamine adducts derived from brain polyunsaturated fatty acids: Mechanism for Parkinson disease. *J Biol Chem.* 2008;283(50):34887-95.
104. Bose A, Beal MF. Mitochondrial dysfunction in Parkinson's disease. *Exp Neurol.* 2015;24(2):103-16.
105. Zhu J, Chu CT. Mitochondrial dysfunction in Parkinson's disease. *J Alzheimers Dis.* 2010;20 (Suppl 2):S325-34.
106. Turrens JF. Mitochondrial formation of reactive oxygen species. *J Physiol.* 2003;552(Pt 2):335-44.
107. Park JS, Davis RL, Sue CM. Mitochondrial dysfunction in Parkinson's disease: New mechanistic insights and therapeutic perspectives. *Curr Neurol Neurosci Rep.* 2018;18(5):21.
108. Reeve AK, Grady JP, Cosgrave EM, Bennison E, Chen C, Hepplewhite PD, et al. Mitochondrial dysfunction within the synapses of substantia nigra neurons in Parkinson's disease. *NPJ Parkinson's disease.* 2018;4(1):1.
109. Murphy MP. How mitochondria produce reactive oxygen species. *Biochem J.* 2009;417(1):1-13.
110. Brandt U. Energy converting NADH: Quinone oxidoreductase (complex I). *Annu Rev Biochem.* 2006;75:69-92.
111. Hattingen E, Magerkurth J, Pilatus U, Mozer A, Seifried C, Steinmetz H, et al. Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. *Brain.* 2009;132(12):3285-97.
112. Votyakova TV, Reynolds IJ. DeltaPsi(m)-dependent and-independent production of reactive oxygen species by rat brain mitochondria. *J Neurochem.* 2001;79(2):266-77.
113. Seth AK, Barrett AB, Barnett L. Granger causality analysis in neuroscience and neuroimaging. *J Neurosci.* 2015;35(8):3293-7.
114. Rana M, De Coo I, Diaz F, Smeets H, Moraes CT. An out-of-frame cytochrome b gene deletion from a patient with Parkinsonism is associated with impaired complex III assembly and an increase in free radical production. *Ann Neurol.* 2000;48(5):774-81.
115. Parker Jr WD, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. *Ann Neurol.* 1989;26(6):719-23.
116. Yoshino H, Nakagawa-Hattori Y, Kondo T, Mizuno Y. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease. *J Neural Transm Park Dis Dement Sect.* 1992;4(1):27-34.
117. Blesa J, Przedborski S. Parkinson's disease: Animal models and dopaminergic cell vulnerability. *Front Neuroanat.* 2014;8:155.
118. Vila M, Przedborski S. Targeting programmed cell death in neurodegenerative diseases. *Nat Rev Neurosci.* 2003;4(5):365-75.
119. Elstner M, Morris CM, Heim K, Bender A, Mehta D, Jaros E, et al. Expression analysis of dopaminergic neurons in Parkinson's disease and aging links transcriptional dysregulation of energy metabolism to cell death. *Acta Neuropathol.* 2011;122(1):75-86.
120. Greenamyre JT, Cannon JR, Drolet R, Mastroberardino PG. Lessons from the rotenone model of Parkinson's disease. *Trends Pharmacol Sci.* 2010;31(4):141-2.
121. Oakley AE, Collingwood JF, Dobson J, Love G, Perrott HR, Edwardson JA, et al. Individual dopaminergic neurons show raised iron levels in Parkinson disease. *Neurology.* 2007;68(21):1820-5.
122. Pickrell AM, Youle RJ. The roles of PINK1, Parkin, and mitochondrial fidelity in Parkinson's disease. *Neuron.* 2015;85(2):257-73.
123. Cook C, Stetler C, Petrucelli L. Disruption of protein quality control in Parkinson's disease. *Cold Spring Harb Perspect Med.* 2012;2(5):a009423.
124. Ransohoff RM. How neuroinflammation contributes to neurodegeneration. *Science.* 2016;353(6301):777-83.
125. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: A target for neuroprotection? *Lancet Neurol.* 2009;8(4):382-97.
126. Cebrián C, Zucca FA, Mauri P, Steinbeck JA, Studer L, Scherzer CR, et al. MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration. *Nat Commun.* 2014;5:3633.
127. Hirsch EC, Vyas S, Hunot S. Neuroinflammation in Parkinson's disease. *Parkinsonism Relat Disord.* 2012;18(Suppl 1):S210-2.
128. Doorn KJ, Moors T, Drukarch B, van de Berg WD, Lucassen PJ, van Dam AM. Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson's disease patients. *Acta Neuropathol Commun.* 2014;2:90.
129. Brodacki B, Staszewski J, Toczyłowska B, Kozłowska E, Drela N, Chalimoniuk M, et al. Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNF α , and INF γ concentrations are elevated in patients with atypical and idiopathic parkinsonism. *Neurosci Lett.* 2008;441(2):158-62.
130. Bandres-Ciga S, Cookson MR. Alpha-synuclein triggers T-cell response. Is Parkinson's disease an autoimmune disorder? *Mov Disord.* 2017;32(9):1327.
131. Anese M, Bot F, Panozzo A, Mirolo G, Lippe G. Effect of ultrasound treatment, oil addition and storage time on lycopene stability and *in vitro* bioaccessibility of tomato pulp. *Food Chem.* 2015;172:685-91.

132. Lee Y, Lee S, Chang SC, Lee J. Significant roles of neuroinflammation in Parkinson's disease: Therapeutic targets for PD prevention. *Arch Pharm Res.* 2019;42(5):416-25.
133. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. *Cell.* 2010;140(6):918-34.
134. Nicoletti A, Fagone P, Donzuso G, Mangano K, Dibilio V, Caponnetto S, et al. Parkinson's disease is associated with increased serum levels of macrophage migration inhibitory factor. *Cytokine.* 2011;55(2):165-7.
135. Mogi M, Togari A, Kondo T, Mizuno Y, Komure O, Kuno S, et al. Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from Parkinsonian brain. *J Neural Transm (Vienna).* 2000;107(3):335-41.
136. Arikanoğlu A, Shugaiv E, Tüzün E, Eraksoy M. Impact of cigarette smoking on conversion from clinically isolated syndrome to clinically definite multiple sclerosis. *Int J Neurosci.* 2013;123(7):476-9.
137. Booth HD, Hirst WD, Wade-Martins R. The role of astrocyte dysfunction in Parkinson's disease pathogenesis. *Trends Neurosci.* 2017;40(6):358-70.
138. Sonninen TM, Hämäläinen RH, Koskuvi M, Oksanen M, Shakirzyanova A, Wojciechowski S, et al. Metabolic alterations in Parkinson's disease astrocytes. *Sci Rep.* 2020;10(1):14474.
139. Gray MT, Woulfe JM. Striatal blood-brain barrier permeability in Parkinson's disease. *J Cereb Blood Flow Metab.* 2015;35(5):747-50.
140. Hernandez DG, Reed X, Singleton AB. Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance. *J Neurochem.* 2016;139(Suppl 1):59-74.
141. Hamby ME, Sofroniew MV. Reactive astrocytes as therapeutic targets for CNS disorders. *Neurotherapeutics.* 2010;7(4):494-506.
142. Rappold PM, Tieu K. Astrocytes and therapeutics for Parkinson's disease. *Neurotherapeutics.* 2010;7(4):413-23.
143. Kang W, Hébert JM. Signaling pathways in reactive astrocytes, a genetic perspective. *Mol Neurobiol.* 2011;43(3):147-54.
144. Gomes MZ, Raisman-Vozari R, Del Bel EA. A nitric oxide synthase inhibitor decreases 6-hydroxydopamine effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostriatal pathway. *Brain Res.* 2008;1203:160-9.
145. González H, Pacheco R. T-cell-mediated regulation of neuroinflammation involved in neurodegenerative diseases. *J Neuroinflammation.* 2014;11:201.
146. Saunders JA, Estes KA, Kosloski LM, Allen HE, Dempsey KM, Torres-Russotto DR, et al. CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease. *J Neuroimmune Pharmacol.* 2012;7(4):927-38.
147. Hernández-Romero MC, Delgado-Cortés MJ, Sarmiento M, de Pablos RM, Espinosa-Oliva AM, Argüelles S, et al. Peripheral inflammation increases the deleterious effect of CNS inflammation on the nigrostriatal dopaminergic system. *Neurotoxicology.* 2012;33(3):347-60.
148. Zhang M, Mu H, Shang Z, Kang K, Lv H, Duan L, et al. Genome-wide pathway-based association analysis identifies risk pathways associated with Parkinson's disease. *Neuroscience.* 2017;340:398-410.
149. Villegas-Llerena C, Phillips A, Garcia-Reitböck P, Hardy J, Pocock JM. Microglial genes regulating neuroinflammation in the progression of Alzheimer's disease. *Curr Opin Neurobiol.* 2016;36:74-81.
150. Dexter DT, Jenner P. Parkinson disease: from pathology to molecular disease mechanisms. *Free Radic Biol Med.* 2013;62:132-44.
151. Mehta SH, Adler CH. Advances in biomarker research in Parkinson's disease. *Curr Neurol Neurosci Rep.* 2016;16(1):7.
152. Sharma S, Moon CS, Khogali A, Haidous A, Chabenne A, Ojo C, et al. Biomarkers in Parkinson's disease (recent update). *Neurochem Int.* 2013;63(3):201-29.
153. van Dijk KD, Teunissen CE, Drukarch B, Jimenez CR, Groenewegen HJ, Berendse HW, et al. Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: A pathogenetically based approach. *Neurobiol Dis.* 2010;39(3):229-41.
154. Parnetti L, Castrioto A, Chiasserini D, Persichetti E, Tambasco N, El-Agnaf O, et al. Cerebrospinal fluid biomarkers in Parkinson disease. *Nat Rev Neurol.* 2013;9(3):131-40.
155. Chang KH, Chen CM. The role of oxidative stress in Parkinson's disease. *Antioxidants (Basel).* 2020;9(7):597.
156. Cesar Tobon-Velasco J, Carmona-Aparicio L, F Ali S, Santamaría A. Biomarkers of cell damage induced by oxidative stress in Parkinson's disease and related models. *Cent Nerv Syst Agents Med Chem.* 2010;10(4):278-86.
157. Simon DK, Simuni T, Elm J, Clark-Matott J, Graebner AK, Baker L, et al. Peripheral biomarkers of Parkinson's disease progression and pioglitazone effects. *J Parkinsons Dis.* 2015;5(4):731-6.
158. Vågberg M, Norgren N, Dring A, Lindqvist T, Birgander R, Zetterberg H, et al. Levels and age dependency of neurofilament light and glial fibrillary acidic protein in healthy individuals and their relation to the brain parenchymal fraction. *PLoS One.* 2015;10(8):e0135886.
159. Pearce RK, Owen A, Daniel S, Jenner P, Marsden CD. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. *J Neural Transm (Vienna).* 1997;104(6-7):661-77.
160. Sharma LK, Lu J, Bai Y. Mitochondrial respiratory complex I: structure, function and implication in human diseases. *Curr Med Chem.* 2009;16(10):1266-77.
161. Mischley LK, Standish LJ, Weiss NS, Padowski JM, Kavanagh TJ, White CC, et al. Glutathione as a biomarker in Parkinson's disease: Associations with aging and disease severity. *Oxid Med Cell Longev.* 2016;2016:9409363.
162. Surendran S. Upregulation of N-acetylaspartic acid alters inflammation, transcription and contractile associated protein levels in the stomach and smooth muscle contractility. *Mol Biol Rep.* 2009;36(1):201-6.
163. Su LJ, Zhang JH, Gomez H, Murugan R, Hong X, Xu D, et al. Reactive oxygen species-induced lipid peroxidation in apoptosis, autophagy, and ferroptosis. *Oxid Med Cell Longev.* 2019;5080843.
164. Çokal BG, Yurtdaş M, Güler SK, Güneş HN, Uçar CA, Aytac B, et al. Serum glutathione peroxidase, xanthine oxidase, and superoxide dismutase activities and malondialdehyde levels in patients with Parkinson's disease. *Neurol Sci.* 2017;38(3):425-31.
165. Seet RC, Lee CY, Lim EC, Tan JJ, Quek AM, Chong WL, et al. Oxidative damage in Parkinson disease: Measurement using accurate biomarkers. *Free Radic Biol Med.* 2010;48(4):560-6.
166. Surendran S, Rajasankar S. Parkinson's disease: Oxidative stress and therapeutic approaches. *Neurol Sci.* 2010;31(5):531-40.
167. Mischley LK, Allen J, Bradley R. Coenzyme Q10 deficiency in patients with Parkinson's disease. *J Neurol Sci.* 2012;318(1-2):72-5.
168. Marti G, Saez N, Corominas M, Cuberas G, Lorenzo C, De Fabregues O, et al. Nigrostriatal degeneration and serum BDNF levels in patients with "de novo" untreated Parkinson's disease. *Mov Disord.* 2016;31.
169. Kostrzewa RM, editor. *Handbook of neurotoxicity.* Springer New York; 2014.
170. Yu ZF, Bruce-Keller AJ, Goodman Y, Mattson MP. Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury *in vivo.* *J Neurosci Res.* 1998;53(5):613-25.

171. Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. *J Neurochem*. 2002;80(1):101-10.
172. Fitzmaurice PS, Ang L, Guttman M, Rajput AH, Furukawa Y, Kish SJ. Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease. *Mov Disord*. 2003;18(9):969-76.
173. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. *Nat Rev Neurosci*. 2004;5(11):863-73.
174. Weisskopf MG, O'reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson's disease. *Am J Epidemiol*. 2007;166(5):561-7.
175. Squadrito GL, Cueto R, Splenser AE, Valavanidis A, Zhang H, Uppu RM, et al. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. *Arch Biochem Biophys*. 2000;376(2):333-7.
176. Costa A, Peppe A, Carlesimo GA, Zabberoni S, Scalici F, Caltagirone C, et al. Brain-derived neurotrophic factor serum levels correlate with cognitive performance in Parkinson's disease patients with mild cognitive impairment. *Front Behav Neurosci*. 2015;9:253.
177. Scalzo P, Kümmer A, Bretas TL, Cardoso F, Teixeira AL. Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson's disease. *J Neurol*. 2010;257(4):540-5.
178. Howells DW, Porritt M, Wong JY, Batchelor PE, Kalnins R, Hughes AJ, et al. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. *Exp Neurol*. 2000;166(1):127-35.
179. Knott C, Stern G, Kingsbury A, Welcher AA, Wilkin GP. Elevated glial brain-derived neurotrophic factor in Parkinson's disease nigra. *Parkinsonism Relat Disord*. 2002;8(5):329-41.
180. Leal G, Afonso PM, Salazar IL, Duarte CB. Regulation of hippocampal synaptic plasticity by BDNF. *Brain Res*. 2015;1621:82-101.
181. Gyárfás T, Knuutila J, Lindholm P, Rantamäki T, Castrén E. Regulation of Brain-Derived Neurotrophic Factor (BDNF) and Cerebral Dopamine Neurotrophic Factor (CDNF) by anti-parkinsonian drug therapy in vivo. *Cell Mol Neurobiol*. 2010;30(3):361-8.
182. Picillo M, Erro R, Santangelo G, Pivonello R, Longo K, Pivonello C, et al. Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson's disease. *J Neurol*. 2013;260(7):1724-30.
183. Sutherland GT, Matigian NA, Chalk AM, Anderson MJ, Silburn PA, Mackay-Sim A, et al. A cross-study transcriptional analysis of Parkinson's disease. *PLoS one*. 2009;4(3):e4955.
184. Godau J, Knauel K, Weber K, Brockmann K, Maetzler W, Binder G, et al. Serum insulin like growth factor 1 as possible marker for risk and early diagnosis of Parkinson disease. *Arch Neurol*. 2011;68(7):925-31.
185. Liu C, Cholerton B, Shi M, Gingham C, Cain KC, Auinger P, et al. CSF tau and tau/A β 42 predict cognitive decline in Parkinson's disease. *Parkinsonism Relat Disord*. 2015;21(3):271-6.
186. Mandel SA, Morelli M, Halperin I, Korczyn AD. Biomarkers for prediction and targeted prevention of Alzheimer's and Parkinson's diseases: Evaluation of drug clinical efficacy. *EPMA J*. 2010;1(2):273-92.
187. Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, Galasko D, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. *Ann Neurol*. 2011;69(3):570-80.